Universität zu Köln

Koehler, Philipp ORCID: 0000-0002-7386-7495, Hamprecht, Axel ORCID: 0000-0003-1449-5780, Bader, Oliver ORCID: 0000-0002-1534-440X, Bekeredjian-Ding, Isabelle ORCID: 0000-0001-6646-5888, Buchheidt, Dieter ORCID: 0000-0002-4425-6134, Doelken, Gottfried, Elias, Johannes ORCID: 0000-0002-5878-7040, Haase, Gerhard ORCID: 0000-0001-7771-3189, Hahn-Ast, Corinna, Karthaus, Meinolf, Kekule, Alexander, Keller, Peter, Kiehl, Michael, Krause, StefanW., Karmer, Carolin, Neumann, Silke, Rohde, Holger, La Rosee, Paul ORCID: 0000-0002-6758-7809, Ruhnke, Markus, Schafhausen, Philippe, Schalk, Enrico ORCID: 0000-0003-1892-5098, Schulz, Katrin, Schwartz, Stefan ORCID: 0000-0001-8833-5793, Silling, Gerda, Staib, Peter, Ullmann, Andrew, Vergoulidou, Maria, Weber, Thomas, Cornely, Oliver A. and Vehreschild, Maria J. G. T. (2017). Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. Int. J. Antimicrob. Agents, 49 (2). S. 218 - 224. AMSTERDAM: ELSEVIER. ISSN 1872-7913

Full text not available from this repository.

Abstract

Invasive aspergillosis (IA) is a serious hazard to high-risk haematological patients. There are increasing reports of azole-resistant Aspergillus spp. This study assessed the epidemiology of IA and azoleresistant Aspergillus spp. in patients with acute leukaemia in Germany. A prospective multicentre cohort study was performed in German haematology/oncology centres. The incidence of probable and proven aspergillosis according to the revised EORTC/MSG criteria was assessed for all patients with acute leukaemia [acutemyeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL)]. Caseswere documented into a web-based case report form, and centres provided data on standards regarding prophylactic and diagnostic measures. Clinical isolates were screened centrally for azole resistance and, if applicable, underlying resistance mechanisms were analysed. Between September 2011 and December 2013, 179 cases of IA [6 proven (3.4%) and 173 probable (96.6%)] were diagnosed in 3067 patients with acuteleukaemia. The incidence of IA was 6.4% among 2440 AML patients and 3.8% among 627 ALL patients. Mortality at Day 84 was 33.8% (49/145) and attributable mortality was 26.9% (39/145). At Day 84, 53 patients (29.6%) showed a complete response, 25 (14.0%) a partial response and 17 (9.5%) a deterioration or failure. A total of 77 clinical Aspergillus fumigatus isolates were collected during the study period. Two episodes of azole-resistant IA (1.1%) were caused by a TR/L98H mutation in the cyp51A gene. With only two cases of IA due to azole-resistant A. fumigatus, a change of antifungal treatment practices in Germany does not appear warranted currently. (C) 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Koehler, Philipp UNSPECIFIED orcid.org/0000-0002-7386-7495 UNSPECIFIED Hamprecht, Axel UNSPECIFIED orcid.org/0000-0003-1449-5780 UNSPECIFIED Bader, Oliver UNSPECIFIED orcid.org/0000-0002-1534-440X UNSPECIFIED Bekeredjian-Ding, Isabelle UNSPECIFIED orcid.org/0000-0001-6646-5888 UNSPECIFIED Buchheidt, Dieter UNSPECIFIED orcid.org/0000-0002-4425-6134 UNSPECIFIED Doelken, Gottfried UNSPECIFIED UNSPECIFIED UNSPECIFIED Elias, Johannes UNSPECIFIED orcid.org/0000-0002-5878-7040 UNSPECIFIED Haase, Gerhard UNSPECIFIED orcid.org/0000-0001-7771-3189 UNSPECIFIED Hahn-Ast, Corinna UNSPECIFIED UNSPECIFIED UNSPECIFIED Karthaus, Meinolf UNSPECIFIED UNSPECIFIED UNSPECIFIED Kekule, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Keller, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Kiehl, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Krause, StefanW. UNSPECIFIED UNSPECIFIED UNSPECIFIED Karmer, Carolin UNSPECIFIED UNSPECIFIED UNSPECIFIED Neumann, Silke UNSPECIFIED UNSPECIFIED UNSPECIFIED Rohde, Holger UNSPECIFIED UNSPECIFIED UNSPECIFIED La Rosee, Paul UNSPECIFIED orcid.org/0000-0002-6758-7809 UNSPECIFIED Ruhnke, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED Schafhausen, Philippe UNSPECIFIED UNSPECIFIED UNSPECIFIED Schalk, Enrico UNSPECIFIED orcid.org/0000-0003-1892-5098 UNSPECIFIED Schulz, Katrin UNSPECIFIED UNSPECIFIED UNSPECIFIED Schwartz, Stefan UNSPECIFIED orcid.org/0000-0001-8833-5793 UNSPECIFIED Silling, Gerda UNSPECIFIED UNSPECIFIED UNSPECIFIED Staib, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Ullmann, Andrew UNSPECIFIED UNSPECIFIED UNSPECIFIED Vergoulidou, Maria UNSPECIFIED UNSPECIFIED UNSPECIFIED Weber, Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Cornely, Oliver A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Vehreschild, Maria J. G. T. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-241686
DOI:	10.1016/j.ijantimicag.2016.10.019
Journal or Publication Title:	Int. J. Antimicrob. Agents
Volume:	49
Number:	2
Page Range:	S. 218 - 224
Date:	2017
Publisher:	ELSEVIER
Place of Publication:	AMSTERDAM
ISSN:	1872-7913
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ACUTE MYELOID-LEUKEMIA; CELL TRANSPLANT RECIPIENTS; DISEASES WORKING PARTY; FUNGAL-INFECTIONS; PRIMARY PROPHYLAXIS; MOLD INFECTIONS; GERMAN SOCIETY; AMPHOTERICIN-B; FUMIGATUS; THERAPY Multiple languages Infectious Diseases; Microbiology; Pharmacology & Pharmacy Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/24168